JP2016518351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518351A5 JP2016518351A5 JP2016506352A JP2016506352A JP2016518351A5 JP 2016518351 A5 JP2016518351 A5 JP 2016518351A5 JP 2016506352 A JP2016506352 A JP 2016506352A JP 2016506352 A JP2016506352 A JP 2016506352A JP 2016518351 A5 JP2016518351 A5 JP 2016518351A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- acid
- group
- lys
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000539 dimer Substances 0.000 claims description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 39
- 150000008574 D-amino acids Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000005647 linker group Chemical group 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 11
- 239000000178 monomer Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- -1 heteroaromatic amino acid Chemical class 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 claims description 6
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000008827 biological function Effects 0.000 claims description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 6
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 230000010933 acylation Effects 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 3
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 3
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 claims description 3
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 claims description 3
- IEXKUCOGQITOPO-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEXKUCOGQITOPO-UHFFFAOYSA-N 0.000 claims description 3
- GDYYIJNDPMFMTB-UHFFFAOYSA-N 2-[3-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(CC(O)=O)=C1 GDYYIJNDPMFMTB-UHFFFAOYSA-N 0.000 claims description 3
- SLWIPPZWFZGHEU-UHFFFAOYSA-N 2-[4-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(CC(O)=O)C=C1 SLWIPPZWFZGHEU-UHFFFAOYSA-N 0.000 claims description 3
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 claims description 3
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 claims description 3
- NCFSMLBHQUAMHH-UHFFFAOYSA-N C1=CN=NN=C1.CC(C)(C)OC(=O)C1=C(C(O)=O)C=CC=C1C(O)=O Chemical compound C1=CN=NN=C1.CC(C)(C)OC(=O)C1=C(C(O)=O)C=CC=C1C(O)=O NCFSMLBHQUAMHH-UHFFFAOYSA-N 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 150000007824 aliphatic compounds Chemical class 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 3
- 150000001491 aromatic compounds Chemical class 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- WRZXKWFJEFFURH-UHFFFAOYSA-N dodecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WRZXKWFJEFFURH-UHFFFAOYSA-N 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims description 3
- 238000009505 enteric coating Methods 0.000 claims description 3
- 150000002390 heteroarenes Chemical class 0.000 claims description 3
- 230000011987 methylation Effects 0.000 claims description 3
- 238000007069 methylation reaction Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 2
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 206010062164 Seronegative arthritis Diseases 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 125000006267 biphenyl group Chemical group 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 208000023819 chronic asthma Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000017760 chronic graft versus host disease Diseases 0.000 claims description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 208000008275 microscopic colitis Diseases 0.000 claims description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical group OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical group 0.000 claims 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000003872 anastomosis Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940122065 Alpha4beta7 integrin antagonist Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 208000011476 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib Diseases 0.000 description 1
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 description 1
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 description 1
- 102100028902 Hermansky-Pudlak syndrome 1 protein Human genes 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000005516 glycogen storage disease Ib Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 201000008105 leukocyte adhesion deficiency 1 Diseases 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361807714P | 2013-04-02 | 2013-04-02 | |
| US61/807,714 | 2013-04-02 | ||
| US14/229,784 | 2014-03-28 | ||
| US14/229,784 US20140294901A1 (en) | 2013-04-02 | 2014-03-28 | Novel a4b7 peptide dimer antagonists |
| PCT/US2014/032391 WO2014165448A1 (en) | 2013-04-02 | 2014-03-31 | NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518351A JP2016518351A (ja) | 2016-06-23 |
| JP2016518351A5 true JP2016518351A5 (https=) | 2017-04-27 |
| JP6499157B2 JP6499157B2 (ja) | 2019-04-10 |
Family
ID=51621089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506352A Active JP6499157B2 (ja) | 2013-04-02 | 2014-03-31 | 新規のα４β７ペプチド二量体アンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20140294901A1 (https=) |
| EP (1) | EP2981544B1 (https=) |
| JP (1) | JP6499157B2 (https=) |
| KR (1) | KR20160011625A (https=) |
| CN (1) | CN105339383A (https=) |
| AU (2) | AU2014248321A1 (https=) |
| CA (1) | CA2908593A1 (https=) |
| HK (1) | HK1221233A1 (https=) |
| SG (2) | SG10201708103RA (https=) |
| WO (1) | WO2014165448A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| WO2016054411A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| KR20180100302A (ko) * | 2015-10-23 | 2018-09-10 | 우니베르지태트 트벤테 | 인테그린 결합 펩티드 및 그의 용도 |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3017926C (en) * | 2016-03-23 | 2023-10-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing .alpha.4.beta.7 peptide antagonists |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2020014646A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7534382B2 (ja) | 2019-07-10 | 2024-08-14 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3167751A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | インターロイキン－２３受容体のペプチド阻害剤の組成物 |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| CN114874107B (zh) * | 2022-07-12 | 2022-11-29 | 中山大学附属第七医院(深圳) | 一种氨基脂质及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037324A (en) * | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| GB9613112D0 (en) * | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| US6818617B1 (en) * | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
| AU750175B2 (en) * | 1997-11-24 | 2002-07-11 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| KR100983997B1 (ko) * | 2001-01-09 | 2010-09-28 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
| GB0610395D0 (en) * | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
| US9193790B2 (en) * | 2006-12-07 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of antagonists of the interaction between HIV GP120 and A4B7 integrin |
| WO2009039185A1 (en) * | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
| JP2011231085A (ja) * | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
| EP2444101A1 (en) * | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
| US9273093B2 (en) * | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
-
2014
- 2014-03-28 US US14/229,784 patent/US20140294901A1/en not_active Abandoned
- 2014-03-31 WO PCT/US2014/032391 patent/WO2014165448A1/en not_active Ceased
- 2014-03-31 SG SG10201708103RA patent/SG10201708103RA/en unknown
- 2014-03-31 CN CN201480028920.2A patent/CN105339383A/zh active Pending
- 2014-03-31 HK HK16109329.5A patent/HK1221233A1/zh unknown
- 2014-03-31 EP EP14779463.0A patent/EP2981544B1/en active Active
- 2014-03-31 CA CA2908593A patent/CA2908593A1/en not_active Abandoned
- 2014-03-31 SG SG11201508178UA patent/SG11201508178UA/en unknown
- 2014-03-31 JP JP2016506352A patent/JP6499157B2/ja active Active
- 2014-03-31 KR KR1020157031177A patent/KR20160011625A/ko not_active Withdrawn
- 2014-03-31 AU AU2014248321A patent/AU2014248321A1/en not_active Abandoned
-
2017
- 2017-12-08 US US15/836,648 patent/US20190002500A1/en not_active Abandoned
-
2018
- 2018-08-27 AU AU2018220168A patent/AU2018220168A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518351A5 (https=) | ||
| JP2016515620A5 (https=) | ||
| JP2017522362A5 (https=) | ||
| RU2017114414A (ru) | НОВЫЕ АНТАГОНИСТЫ α4β7 НА ОСНОВЕ МОНОМЕРНЫХ И ДИМЕРНЫХ ПЕПТИДОВ | |
| JP2015533833A5 (https=) | ||
| JP2017535527A5 (https=) | ||
| TWI674271B (zh) | 新穎之調酸素衍生物及含有該衍生物之用於治療肥胖之醫藥組成物 | |
| US12077612B2 (en) | Peptide compositions | |
| TWI608013B (zh) | 升糖素類似物 | |
| JP2025163134A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| AU2014228460B2 (en) | Pharmaceutical compositions | |
| JP6499157B2 (ja) | 新規のα４β７ペプチド二量体アンタゴニスト | |
| JP2012067099A5 (https=) | ||
| CA2955460A1 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| JP2020007339A (ja) | α４β７インテグリンチオエーテルペプチドアンタゴニスト | |
| JP2017530090A5 (https=) | ||
| KR20160068951A (ko) | 글루카곤 유사체 | |
| JP2016515620A (ja) | 新規のα４β７ペプチド拮抗薬 | |
| JP2012529296A5 (https=) | ||
| EP2525809A1 (en) | Treatment of cardiac conditions | |
| KR20220110789A (ko) | 칼슘 감지 수용체 효능제 화합물 및 이의 응용 | |
| WO2022188628A1 (zh) | 一类阿片/神经肽ff受体多靶点环肽分子及其制备和应用 | |
| US6596692B1 (en) | Substance P analogs for the treatment of cancer | |
| WO2025137159A1 (en) | Human interleukin (il)-17 cytokine binding peptides | |
| WO2026060110A1 (en) | Dual- and tri-agonist compounds for obesity & t2dm |